Organisation paid for research Program year 2025 Source: CMS Open Payments

Pioneer Research Solutions Inc

Neither a doctor nor a teaching hospital

Research payments

$12,059,345

1,606 payments

Through program year 2025, Pioneer Research Solutions Inc is reported as receiving $12,059,345 in research payments, across 1,606 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $6,624,433 241
2024 Research $1,034,021 134
2023 Research $588,220 318
2022 Research $1,005,758 565
2021 Research $621,391 94
2020 Research $630,355 109
2019 Research $1,555,167 145

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $5,855,413 8 payments
  2. Regeneron Pharmaceuticals, Inc. $2,233,097 998 payments
  3. AbbVie, Inc. $723,093 207 payments
  4. Novartis Pharmaceuticals Corporation $674,293 8 payments
  5. Astellas Pharma Global Development $645,642 69 payments
  6. AstraZeneca UK Limited $595,316 11 payments
  7. Allergan Inc. $409,701 46 payments
  8. Ardelyx, Inc. $261,161 92 payments
  9. Sanofi US Services Inc. $123,064 29 payments
  10. AstraZeneca Pharmaceuticals LP $115,553 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $5,570,604 1 payment
  2. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $937,383 69 payments
  3. A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms $645,642 69 payments
  4. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $352,990 29 payments
  5. M16-100 $300,793 36 payments
  6. A Master Protocol of Randomized, Double-Blind, Placebo-Controlled, Phase 2 Studies of siRNA Gene Silencing for the Treatment of Non- Alcoholic Steatohepatitis (NASH) in Participants With Genetic Risk Factors $294,428 83 payments
  7. Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $284,677 720 payments
  8. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $268,633 3 payments
  9. A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease $246,583 4 payments
  10. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $238,239 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record